Pathology: la/mBC - HER2 positive - 1st Line (L1); la/mBC - HR-positive - 1st line (L1);
| la/mBC - HER2 positive - 1st Line (L1) | la/mBC - HR-positive - 1st line (L1) | ||
| AVEREL, 2013 | NCT00454805, 2013 | ||
| bevacizumab plus trastuzumab plus docetaxel | 1 | T1 | |
| cediranib plus fulvestrant | 1 | T1 | |
| trastuzumab plus docetaxel | 0 | T0 | |
| fulvestrant | 0 | T0 |